Neuland Laboratories Limited Share Price

Equities

NEULANDLAB

INE794A01010

Pharmaceuticals

Delayed Bombay S.E. 01:53:25 13/06/2024 pm IST 5-day change 1st Jan Change
6,561 INR +3.13% Intraday chart for Neuland Laboratories Limited +6.53% +23.72%
Sales 2024 15.59B 187M Sales 2025 * 15.98B 191M Capitalization 81.62B 977M
Net income 2024 3B 35.93M Net income 2025 * 3.02B 36.12M EV / Sales 2024 5.17 x
Net cash position 2024 * 2.32B 27.83M Net cash position 2025 * 3.57B 42.72M EV / Sales 2025 * 4.88 x
P/E ratio 2024
26.9 x
P/E ratio 2025 *
27.2 x
Employees 1,554
Yield 2024 *
0.19%
Yield 2025 *
0.15%
Free-Float 62.32%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.82%
1 week+6.53%
Current month+8.30%
1 month+7.98%
3 months+15.87%
6 months+25.26%
Current year+23.72%
More quotes
1 week
6 175.60
Extreme 6175.6
6 644.30
1 month
5 557.00
Extreme 5557
6 644.30
Current year
5 029.80
Extreme 5029.8
7 794.00
1 year
2 730.00
Extreme 2730
7 794.00
3 years
965.85
Extreme 965.85
7 794.00
5 years
247.30
Extreme 247.3
7 794.00
10 years
247.30
Extreme 247.3
7 794.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 01/02/01
Director of Finance/CFO - 23/22/23
Chief Tech/Sci/R&D Officer - 22/11
Members of the board TitleAgeSince
Director/Board Member 78 31/22/31
Director/Board Member 80 12/19/12
Director/Board Member 60 27/23/27
More insiders
Date Price Change Volume
13/24/13 6,561 +3.13% 2 697
12/24/12 6,362 -2.15% 1,807
11/24/11 6,502 +3.79% 1,345
10/24/10 6,264 -0.55% 2,005
07/24/07 6,299 +2.58% 845

Delayed Quote Bombay S.E., June 13, 2024 at 01:53 pm IST

More quotes
Neuland Laboratories Limited is an India-based company. The Company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The Company is an active pharmaceutical ingredient (API) manufacturing and development organization that caters to the pharmaceutical and biotech industry’s chemistry needs. It provides solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying New Chemical Entities (NCEs) and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its key molecules include Mirtazapine, an anti-depressant and Levetiracetam, an anti-epileptic agent. The Company’s product portfolio includes over 100 APIs across 10 diverse therapeutic areas.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6,362 INR
Average target price
8,300 INR
Spread / Average Target
+30.46%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NEULANDLAB Stock